Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The protocol was amended to limit the sample size from 339 to 100. 111 entered the study and and were part of the 12 mo analysis. The study was subsequently terminated. The patients did not receive study drug during the second year of the study.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Verteporfin + 1 mg Triamcinolone	Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Verteporfin + 4 mg Triamcinolone	Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Verteporfin + Pegaptanib	Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.

Participant Flow:   Overall Study

	Verteporfin + 1 mg Triamcinolone	Verteporfin + 4 mg Triamcinolone	Verteporfin + Pegaptanib
STARTED	32	41	38
COMPLETED	22 [1]	29	24
NOT COMPLETED	10	12	14
Adverse Event	3	0	2
Unsatisfactory therapeutic effect	4	5	5
Protocol Violation	0	0	1
Subject withdrew consent	2	2	5
Lost to Follow-up	0	3	0
Adminstrative problems	0	0	0
Death	1	2	1

Reporting Groups

	Description
Verteporfin + 1 mg Triamcinolone	Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Verteporfin + 4 mg Triamcinolone	Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Verteporfin + Pegaptanib	Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.

Baseline Measures

	Verteporfin + 1 mg Triamcinolone	Verteporfin + 4 mg Triamcinolone	Verteporfin + Pegaptanib	Total
Number of Participants   [units: participants]	32	41	38	111
Age   [units: years] Mean ± Standard Deviation	76  ± 9	78  ± 8	81  ± 6	78  ± 8
Gender   [units: participants]
Female	18	25	20	63
Male	14	16	18	48
Region of Enrollment   [units: participants]
United States	32	41	38	111

1.  Primary:

Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.   [ Time Frame: Baseline to Month 12 ]

2.  Secondary:

Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12   [ Time Frame: Baseline to Month 12 ]

3.  Secondary:

Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months   [ Time Frame: Baseline to Month 12 ]

4.  Secondary:

Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12   [ Time Frame: Baseline to Month 12 ]

5.  Secondary:

Number of Participants Requiring Verteporfin Treatment Throughout the Study   [ Time Frame: Baseline to Month 12 ]

6.  Secondary:

Mean Change From Baseline in Total Area of Lesion at 12 Months   [ Time Frame: Baseline to Month 12 ]